|

Amivantamab Clinical Trials

14 actively recruiting trials across 7 locations

▼ -1 trial since July 2026

Also known as: Amivantamab-vmjw, Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372, CNTO-4424, JNJ 61186372, JNJ-372 +5 more

Pipeline

Phase 1: 1Phase 2: 7Phase 3: 3Phase 1/2: 3

Top Sponsors

  • Janssen Research & Development, LLC9
  • Vall d'Hebron Institute of Oncology1
  • SWOG Cancer Research Network1
  • Institute of Cancer Research, United Kingdom1
  • Gruppo Oncologico del Nord-Ovest1

Indications

  • Cancer14
  • Lung Cancer6
  • Carcinoma, Non-Small-Cell Lung4
  • Squamous Cell Carcinoma of Head and Neck2
  • Colorectal Neoplasms2

Other5 trials

5G-EMERALD: Amivantamab in Malignant Brain Tumours
Phase 1
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Phase 2
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Phase 2
Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
Phase 2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Phase 2

Chandler, Arizona2 trials

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Ironwood Cancer and Research Center

Phase 3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Ironwood Cancer and Research Center

Phase 3

La Jolla, California2 trials

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

University of California at San Diego Moores Cancer Center

Phase 1/2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

University of California at San Diego

Phase 2

Birmingham, Alabama1 trial

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

O Neal Comprehensive Cancer Center at UAB

Phase 1/2

Daphne, Alabama1 trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Southern Cancer Center, PC

Phase 2

Gilbert, Arizona1 trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Banner MD Anderson Cancer Center

Phase 3

Jonesboro, Arkansas1 trial

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

Phase 2

New York, New York1 trial

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

New York University Langone Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.